Non-coding RNAs/DNMT3B axis in human cancers: from pathogenesis to clinical significance

Abstract

Cancer is a complex disease with many contributing factors, and researchers have gained extensive knowledge that has helped them understand the diverse and varied nature of cancer. The altered patterns of DNA methylation found in numerous types of cancer imply that they may play a part in the disease’s progression. The human cancer condition involves dysregulation of the DNA methyltransferase 3 beta (DNMT3B) gene, a prominent de novo DNA methyltransferase, and its abnormal behavior serves as an indicator for tumor prognosis and staging. The expression of non-coding RNAs (ncRNAs), which include microRNAs (miRNA), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), is critical in controlling targeted gene expression and protein translation and their dysregulation correlates with the onset of tumors. NcRNAs dysregulation of is a critical factor that influences the modulation of several cellular characteristics in cancerous cells. These characteristics include but are not limited to, drug responsiveness, angiogenesis, metastasis, apoptosis, proliferation, and properties of tumor stem cell. The reciprocal regulation of ncRNAs and DNMT3B can act in synergy to influence the destiny of tumor cells. Thus, a critical avenue for advancing cancer prevention and treatment is an inquiry into the interplay between DNMT3B and ncRNAs. In this review, we present a comprehensive overview of the ncRNAs/DNMT3B axis in cancer pathogenesis. This brings about valuable insights into the intricate mechanisms of tumorigenesis and provides a foundation for developing effective therapeutic interventions.

Crosstalk between MiRNAs/lncRNAs and PI3K/AKT signaling pathway in diabetes mellitus: Mechanistic and therapeutic perspectives

“…This observation leads to speculation that the notable distinctions in organism complexity between higher and lower organisms could potentially stem from the substantial variations in noncoding transcripts. Many of these noncoding transcripts undergo intricate processing, resulting in the generation of smaller noncoding RNA entities, such as miRNA and lncRNA [ 41 ]. By engaging with proteins, RNA, and DNA noncoding RNAs have arisen as pivotal modulators of gene expression in both pathological and physiological conditions.…”

CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis

“…The advent of targeted therapies has markedly prolonged the survival of patients with mutations in key driver genes such as EGFR, ALK, MET, ROS1, RET, and HER2 [ 3 ]. Nevertheless, a significant fraction of LUAD patients do not possess these mutations, highlighting the critical need for identifying new actionable driver genes [ 4 – 6 ].…”

Genomic landscape and distinct molecular subtypes of primary testicular lymphoma

“…Contrastingly, Minderman's study revealed expression of PD-L1 or 9p24.1/PD-L1/2 CNA was detected in only a small number of samples. In addition, their team extracted PD-L1 messenger RNA (mRNA) expression data from publicly available databases for validation, and they found that there was no enhancement of PD-L1 expression in PTL compared to primary mediastinal B-cell lymphomas (PMBCLs) [ 16 – 19 ]. Instead, HLA deletions were common in their PTL cohort.…”